See more : Canoo Holdings Ltd. (GOEVW) Income Statement Analysis – Financial Results
Complete financial analysis of Salarius Pharmaceuticals, Inc. (SLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Salarius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Andlauer Healthcare Group Inc. (ANDHF) Income Statement Analysis – Financial Results
- RenovaCare, Inc. (RCAR) Income Statement Analysis – Financial Results
- Hugel, Inc. (145020.KQ) Income Statement Analysis – Financial Results
- AmmPower Corp. (AMMP.CN) Income Statement Analysis – Financial Results
- Chalice Mining Limited (CHN.AX) Income Statement Analysis – Financial Results
Salarius Pharmaceuticals, Inc. (SLRX)
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.84M | 5.23M | 3.47M | 838.00K | 1.28M | 1.01M | 0.00 |
| Cost of Revenue | 10.05K | 6.68K | 19.18K | 6.91K | 4.02K | 431.00K | 507.00K | 663.00K | 49.88K |
| Gross Profit | -10.05K | -6.68K | 1.82M | 5.23M | 3.46M | 407.00K | 768.00K | 348.00K | -49.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 98.96% | 99.87% | 99.88% | 48.57% | 60.24% | 34.42% | 0.00% |
| Research & Development | 7.17K | 15.84M | 8.55M | 6.91M | 4.02M | 11.91M | 16.99M | 20.38M | 12.75M |
| General & Administrative | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 2.35M | 1.37M | 797.49K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.22M | 17.14M | 19.06M | 0.00 |
| SG&A | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 10.57M | 18.50M | 19.86M | 16.46M |
| Other Expenses | 0.00 | 8.87M | -4.00 | -178.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.48M | 35.49M | 40.23M | 29.21M |
| Cost & Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.91M | 36.00M | 40.90M | 29.21M |
| Interest Income | 352.25K | 218.73 | 0.00 | 0.00 | 15.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.05K | 6.68K | 19.18K | 18.06K | 16.93K | 16.95K | 324.55K | 277.23K | 49.88K |
| EBITDA | -12.88K | -31.60M | -12.75M | -7.33M | -6.92M | -22.07M | -34.11M | -39.89M | -29.09M |
| EBITDA Ratio | 0.00% | 0.00% | -698.70% | -149.97% | -272.69% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Operating Income | -12.89K | -31.84M | -12.81M | -7.79M | -9.58M | -22.07M | -34.73M | -39.89M | -29.21M |
| Operating Income Ratio | 0.00% | 0.00% | -696.27% | -148.78% | -276.37% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Total Other Income/Expenses | 352.25 | 233.18K | 44.69K | 434.09K | 1.33M | 152.01K | 291.96K | 393.11K | 72.00K |
| Income Before Tax | -12.54K | -31.61M | -12.77M | -7.35M | -6.94M | -21.92M | -34.43M | -39.49M | -29.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | -693.84% | -140.49% | -200.23% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| Income Tax Expense | 0.00 | -233.18K | -63.88K | -255.50K | -1.33M | 152.01K | -324.58K | -277.12K | -49.85K |
| Net Income | -12.54K | -31.37M | -12.70M | -7.10M | -5.61M | -21.92M | -34.43M | -39.49M | -29.14M |
| Net Income Ratio | 0.00% | 0.00% | -690.37% | -135.61% | -161.88% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| EPS | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| EPS Diluted | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| Weighted Avg Shares Out | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
| Weighted Avg Shares Out (Dil) | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?
Genomic therapeutic specialist Salarius Pharmaceuticals (NASDAQ: SLRX ) screamed higher Tuesday, with shares gaining 160% before paring back some of the gains to around 90%. Although no catalyst is apparent, the biotechnology firm revealed details about its at-the-market (ATM) offering...
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial...
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023...
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
The trial will assess the safety and preliminary efficacy of Salarius' novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has closed...
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has entered...
Source: https://incomestatements.info
Category: Stock Reports